CONCORDBIO-Stage 1 Base Breakout / Early Stage 2 Continuation

Concord Biotech appears to be transitioning from a prolonged Stage 1 accumulation into the early stages of a potential Stage 2 uptrend. After spending several months building a broad base following a lengthy decline, the stock delivered an initial breakout, followed by a healthy consolidation that allowed moving averages to catch up. Price has now broken out once again, suggesting buyers continue to absorb supply as the new uptrend develops.

Technical Observations

• Stage 1 Accumulation Complete: After a prolonged downtrend, price spent several months building a broad accumulation base, indicating the possibility of institutional accumulation.
• Early Stage 2 Transition: Price has successfully broken above the Stage 1 base and is beginning to establish a new series of higher highs and higher lows.
• Constructive Continuation Pattern: Rather than extending too far after the initial breakout, the stock consolidated in a tight range before delivering a second breakout, reflecting healthy trend development.
• Moving Average Alignment: Short-term moving averages have crossed above the intermediate-term averages, while the 200 DMA has flattened and is beginning to turn upward, supporting a positive structural shift.
• Improving Relative Strength: Relative Strength has moved decisively into positive territory, suggesting improving market leadership after months of underperformance.
• Volume Behaviour: Breakout participation has improved, although sustained higher-than-average volume on future advances would further strengthen the bullish case.
• Overhead Supply: Previous distribution between ₹1,600–1,650 remains the next significant resistance area and should be monitored as price advances.

Key Levels

• Immediate Support: ₹1,285–1,300
• Major Support: ₹1,220–1,240
• Aggressive Entry: Above ₹1,430
• Stop Loss: Below ₹1,285
• Target 1: ₹1,550–1,600
• Target 2: ₹1,700–1,800 (subject to clearing major overhead supply)

Trade Plan

Aggressive traders may consider initiating positions above ₹1,430 as the stock confirms the continuation breakout from its recent consolidation. The setup offers an attractive risk-to-reward profile with a clearly defined invalidation level beneath recent support.

A stop loss below ₹1,285 would invalidate the current continuation structure and suggest the breakout requires additional consolidation before another attempt higher.

Summary

Concord Biotech is displaying many of the characteristics associated with an emerging Stage 2 leader: completion of a multi-month Stage 1 base, improving relative strength, constructive moving average alignment, and successful continuation following the initial breakout. While significant overhead supply remains near ₹1,600–1,650, sustained strength above current levels could mark the beginning of a larger trend advance.

Disclaimer: Educational purpose only. Not a recommendation to buy or sell securities. Please manage risk appropriately.